Edition:
United Kingdom

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

8.03USD
19 Jan 2018
Change (% chg)

$0.02 (+0.25%)
Prev Close
$8.01
Open
$8.00
Day's High
$8.06
Day's Low
$7.83
Volume
654,214
Avg. Vol
828,077
52-wk High
$8.84
52-wk Low
$2.20

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $768.71
Shares Outstanding(Mil.): 112.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

08 Jan 2018

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-ImmunoGen reports Q3 loss per share $0.61

* ImmunoGen reports recent progress and third quarter 2017 operating results

03 Nov 2017

BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

* Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

16 Oct 2017

BRIEF-Immunogen prices offering of 14.5 mln common shares at $6.50 per share

* Immunogen announces pricing of public offering of common stock

06 Oct 2017

BRIEF-Immunogen- As of Sept. 30, had cash and cash equivalents of about $194.9 mln

* Immunogen- on Oct, 4,, co disclosed that it expects to report that as of Sept. 30, 2017 it had cash and cash equivalents of about $194.9 million Source: (http://bit.ly/2gcIozK) Further company coverage:

04 Oct 2017

BRIEF-ImmunoGen intends to offer and sell 13 mln shares of common stock​

* ImmunoGen announces proposed public offering of common stock

04 Oct 2017

BRIEF-Immunogen enters privately negotiated exchange agreements

* Immunogen-‍on Sept 25, co entered privately negotiated exchange agreements with some holders of co's outstanding 4.50% convertible senior notes due 2021​

26 Sep 2017

BRIEF-ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock

* ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock

01 Sep 2017

BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products

* Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products

29 Aug 2017

Competitors

Earnings vs. Estimates